Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery: A Real-World Experience

Purpose: The neoadjuvant use of pertuzumab and trastuzumab with chemotherapy improves the pathologic complete response (pCR) in early HER2+ breast cancer. The aim of this study was to determine the pCR rate obtained with dual HER2 blockade in routine clinical practice. The secondary and tertiary obj...

Descripción completa

Detalles Bibliográficos
Autores principales: Boér, Katalin, Kahán, Zsuzsanna, Landherr, László, Csőszi, Tibor, Máhr, Károly, Ruzsa, Ágnes, Horváth, Zsolt, Budai, Barna, Rubovszky, Gábor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Society Journal Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262177/
https://www.ncbi.nlm.nih.gov/pubmed/34257621
http://dx.doi.org/10.3389/pore.2021.1609785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262177/
https://www.ncbi.nlm.nih.gov/pubmed/34257621
http://dx.doi.org/10.3389/pore.2021.1609785

Ejemplares similares